News
06-22-2012, 11:31 PM
Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
More... (http://www.news-medical.net/news/20120623/Genentechs-Perjeta-helps-people-with-HER2-positive-metastatic-breast-cancer-live-longer.aspx)
More... (http://www.news-medical.net/news/20120623/Genentechs-Perjeta-helps-people-with-HER2-positive-metastatic-breast-cancer-live-longer.aspx)